Despite the lack of clinical relevance in some cases, the combined therapies of MEK inhibitors, with antibodies targeting PD-1, PD-L1, or CTLA-4, have been explored and demonstrated to exert higher anti-tumor effects than monotherapies [1,60,71]. This evidence concerns the gene CD274 and neoplasm.